Lyrica approved for use in GAD

The licensed indications for Lyrica (pregabalin) have been extended to include the treatment of generalised anxiety disorder (GAD).

The recommended adult dose for use in the new indication is 150 to 600mg daily in two or three divided doses. The dose should be started at 150mg daily then, based on the patient's response, titrated in 150mg daily increments at weekly intervals to a maximum of 600mg daily.

Relief of symptoms may be expected within one week. The need for continued treatment should be reassessed regularly.

Lyrica is also indicated for use as adjunctive therapy in epilepsy for partial seizures with or without secondary generalisation and is available in seven different strengths: 25mg, 50mg, 75mg, 100mg, 150mg, 200mg and 300mg.

Further information: Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS. Tel: (01304) 616161.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Additional tiotropium inhaler available to prescribe

Additional tiotropium inhaler available to prescribe

Acopair is delivered by the dry powder NeumoHaler device.

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

New and deleted indications - live tracker

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...